> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# PureTech Gets Fast Track on LYT-200
- URL: https://www.fdaweb.com/puretech-gets-fast-track-on-lyt-200/
- Published: 2024-04-12T12:00:00.000Z
- Updated: 2026-09-14T14:28:12.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5156766

FDA has granted PureTech Health a fast-track designation for LYT-200 in combination with anti-PD1 therapy for treating recurrent/metastatic head and neck squamous cell carcinomas.

LYT-200 is described as an antibody against galectin-9, a potent cancer driver. It is being evaluated in two ongoing clinical trials — a Phase 1/2 adaptive design trial in advanced/metastatic solid tumors, including head and neck cancers, and a Phase 1b clinical trial evaluating LYT-200 as a monotherapy and in combination with venetoclax and hypomethylating agents in hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome.